Thromb Haemost 1982; 47(02): 177-181
DOI: 10.1055/s-0038-1657157
Original Article
Schattauer GmbH Stuttgart

Problems by Using Whole Blood in Heparin Measurements

Ingebrigt Talstad
The Haematological Division, Medical Department B, Haukeland Hospital, University of Bergen, Bergen, Norway
› Author Affiliations
Further Information

Publication History

Received 19 January 1982

Accepted 03 March 1982

Publication Date:
13 July 2018 (online)

Summary

Problems by using whole blood (WB) of various packed cell volume (PCV) in heparin measurements were studied. WB had to be used within 1 hr, due to influence of platelet Factor 4. The increase of Ca++ by increasing PCV, had a moderate influence by the assays studied. The recalcification time (RT) of WB was timeconsuming and had low accuracy and precision, due to different heparin response. The activated partial thromboplastin time (APTT) also had low accuracy and precision, due to different heparin response; the results were equal for WB and plasma. The thrombin clotting time (TCT) had high accuracy and precision in plasma. The TCT could also be used for WB since there was a good correlation between T20 (20 NTH U thrombin/ml) using WB, and T30 using plasma (r = 0.89, N = 61). The calcium thrombin clotting time (CaTCT) is not recommended for WB assaying.

 
  • References

  • 1 Fanning JP, Dubeau AM. The whole blood recalcification clotting time. A suggested simple and reliable method for monitoring heparin therapy. J Maine Med Assoc 1974; 65: 211-213
  • 2 Gulliani GL, Hyun BH, Litten MB. Blood recalcification time. A simple and reliable test to monitor heparin therapy. Am J Clin Pathol 1976; 65: 390-396
  • 3 Kennedy C, Rocks MJ. Bedside control of heparin therapy by a simple whole blood clotting method. J Clin Pathol 1973; 26: 893-894
  • 4 Makary AZ, Waterbury L. The activated partial thromboplastin time as a monitor of heparin therapy: A warning. J Hopk Med J 1977; 140: 311-315
  • 5 Bull MH, Huse WM, Bull BS. Evaluation of tests used to monitor heparin therapy during extracorporeal circulation. Anesthesiol 1975; 43: 346-353
  • 6 Congdon JE, Kardinal CG, Wallin JD. Monitoring heparin therapy in hemodialysis. A report on the activated whole blood coagulation time tests. JAMA 1973; 226: 1529-1533
  • 7 Grosky BM. Simplified procedure for monitoring heparin therapy. Am J Med Technol 1973; 39: 1-8
  • 8 Handley AJ. Heparin therapy: A simpler test of control. J Clin Pathol 1974; 27: 250-252
  • 9 Ray PK, Abbott D. A modified whole blood partial thromboplastin test for the assessment of heparinization. Can Med Assoc J 1973; 108: 1505-1508
  • 10 Reno WJ, Rotman M, Grumbine FC, Dennis LH, Mohler ER. Evaluation of the BART test (a modification of the whole-blood activated recalcification time test) as a means of monitoring heparin therapy. Am J Clin Pathol 1974; 61: 78-84
  • 11 Wilhelmsson S, Lins LE. Whole-blood thrombin time: a bedside method for determination of heparin activity. Clin Nephrol 1976; 6: 523-525
  • 12 Talstad I. A new principle in heparin assaying based on partial neutralization of heparin with polybrene. Thromb Res 1980; 18: 485-491
  • 13 Ødegaard OR. Evaluation of an amidolytic heparin cofactor assay method. Thromb Res 1975; 7: 351-360
  • 14 Michalski R, Lane DA, Pepper DS, Kakkar VV. Neutralization of heparin in plasma by platelet Factor 4 and protamine sulphate. Brit J Haematol 1978; 38: 561-571
  • 15 Hoffmann JJML, Meulendijk PN. Comparison of reagents for determining the activated partial thromboplastin time. Thromb Haemostas 1978; 39: 640-645
  • 16 Glynn MFX. Heparin monitoring and thrombosis. Am J Clin Pathol 1979; 71: 397-400
  • 17 Talstad I. The non-specific effects of plasmaproteins in clotting assaying. 312 Int Soc Haematol (Abstract) Athens 1981;